跳转至内容
Merck
CN

Y0001809

吉非替尼

European Pharmacopoeia (EP) Reference Standard

别名:

吉非替尼

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C22H24ClFN4O3
化学文摘社编号:
分子量:
446.90
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

吉非替尼, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)

SMILES string

COC(C=C(N=CN=C1NC2=CC(Cl)=C(F)C=C2)C1=C3)=C3OCCCN4CCOCC4

InChI key

XGALLCVXEZPNRQ-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

gefitinib

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... EGFR(1956)

正在寻找类似产品? 访问 产品对比指南

Other Notes

可能适用相应的销售限制。

Packaging

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

Application

吉非替尼,用于系统适用性(EP参考标准品)仅用于欧洲药典中明确规定的实验室测试用途。

General description

本品按现行药典规定交付。所有本产品相关的支持信息,包括SDS和任何产品信息宣传册,均是在药典的授权下制定和发布的。
如需进一步信息和支持,请访问现行药典网站。

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 1 - Carc. 2 - Eye Dam. 1 - Repr. 1B - Skin Irrit. 2 - STOT RE 2 Oral

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Chung-Yu Huang et al.
Cancers, 12(1) (2020-01-16)
Targeted therapy is an efficient treatment for patients with epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). Therapeutic resistance invariably occurs in NSCLC patients. Many studies have focused on drug resistance mechanisms, but only a few
Hee Sun Park et al.
Cancer medicine, 10(4), 1405-1417 (2021-01-25)
Despite the progress of advanced target therapeutic agents and immune checkpoint inhibitors, EGFR-TKI resistance is still one of the biggest obstacles in treating lung cancer. Clinical studies with autophagy inhibitors are actively underway to overcome drug resistance. We used PC9
Philip Bischoff et al.
iScience, 23(11), 101683-101683 (2020-11-10)
Estrogens play an important role in the development and progression of human cancers, particularly in breast cancer. Breast cancer progression depends on the malignant destabilization of adherens junctions (AJs) and disruption of tissue integrity. We found that estrogen receptor alpha
Fadi Jacob et al.
Cell, 180(1), 188-204 (2019-12-31)
Glioblastomas exhibit vast inter- and intra-tumoral heterogeneity, complicating the development of effective therapeutic strategies. Current in vitro models are limited in preserving the cellular and mutational diversity of parental tumors and require a prolonged generation time. Here, we report methods for

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持